Latest Us Expansion News

Galilee Energy has confirmed the final location for its Zydeco-1 well in Louisiana, targeting significant gas and condensate resources with drilling set for the second quarter of 2026. The well also aims to explore additional oil potential, optimising costs and environmental impact.

The US International Trade Commission has overturned preliminary findings and declined to impose steep tariffs on Chinese graphite anode materials, complicating Syrah Resources’ plans to scale up its US-based production facility.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

BetMakers Technology Group Ltd reported an 11.4% rise in half-year revenue to $46.1 million alongside a dramatic 80% reduction in losses, setting the stage for accelerated global growth and a strategic US market push.

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.

StepChange Holdings Limited reports a strong half-year performance post-IPO, with $24.36 million in revenue and a net profit of $524,400, underpinned by key acquisitions and US expansion.

Beforepay Group Limited reported a robust half-year performance with revenues climbing 18.7% and profit after tax nearly doubling, driven by growth in lending volumes and strategic expansion of its Carrington Labs credit analytics business.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Olympio Metals has secured binding agreements to acquire two historically high-grade silver and antimony projects in the US, backed by a $3 million capital raise including vendor participation.